On November 5, 2026, Beijing Jingzhi Pharmaceutical Technology Co., Ltd. (“JINGZHIYIYAO”) signed an exclusive licensing agreement with Jiangsu Xihong Biopharma Co., Ltd. (“Xihong Biopharma”) for XH308, gaining sole and exclusive commercialization rights in mainland China, including promotion and sales, while expanding its regenerative materials portfolio.

JINGZHIYIYAO will pay licensing consideration to Xihong Pharma, which will manufacture and supply the product during the license term. Both will combine strengths in brand building, market operations, and R&D/manufacturing to commercialize XH308 in mainland China.

Photo: Signing ceremony for the JINGZHIYIYAO–Xihong Biopharma exclusive licensing agreement for XH308. Ms. Li Jing, Chairwoman of JINGZHIYIYAO (right), and Mr. Zhang Tianming, General Manager of Xihong Biopharma (left).

This partnership is a key step for JINGZHIYIYAO to enrich its regenerative portfolio, leveraging its brand and market experience. JINGZHIYIYAO has long supported Elravie® and Dermashine® through brand building, academic exchanges and market services. With over a decade in China and 1,000+ institutional partners, it has gained deep market insight and extensive service experience to support XH308 commercialization.

Ms. Li Jing, Chairwoman of JINGZHIYIYAO, said: “We focus on innovative technologies and products that meet clinical needs and offer long-term value. This collaboration expands our regenerative footprint and portfolio. By leveraging each partner’s strengths, we will connect innovation with market demand and, grounded in science and compliance, steadily advance commercialization to create long-term industry value.”

Photo: Ms. Li Jing, Chairwoman of JINGZHIYIYAO.

As R&D and manufacturing partner, Xihong Biopharma has long focused on regenerative medicine materials, with a platform covering multiple materials and ongoing work in process optimization and technology translation—the source of XH308. The partnership will connect material innovation, manufacturing and market promotion to support sustainable growth.

Mr. Zhang Tianming, GM of Xihong Biopharma, said: “Regenerative medicine value rests on materials and process expertise plus clinical and market performance. Xihong has invested in the former for years; Jingzhi has deep experience in the latter. We look forward to advancing XH308’s commercialization in the licensed territory with professionalism and patience.”

Photo: Mr. Zhang Tianming, General Manager of Xihong Biopharma.

This signing launches strategic collaboration between JINGZHIYIYAO and Xihong Biopharma, combining expertise to advance the project. For JINGZHIYIYAO, it applies long-term brand experience to innovative product deployment and supports product value through sustained investment.

About Xihong Biopharma

Founded in 2016, Xihong Biopharma is a wholly owned subsidiary of Dongfang Yanmei, a healthcare company focused on R&D, manufacturing and commercialization of regenerative medicine devices and foods for special medical purposes (FSMP). It develops, translates and applies regenerative materials, and conducts FSMP R&D, especially disease-specific full-nutrition formulas.

Xihong Biopharma’s manufacturing base references China GMP, EU MDR and U.S. FDA device standards and follows GB 29923-2023 for FSMP. Its regenerative medicine device workshop has an annual capacity of up to 10 million doses, making it one of China’s largest regenerative material production lines. Its microfluidic line recently began operation, placing it among the first in China’s regenerative medicine field to operate such a line.

Dongfang Yanmei continues to advance regenerative materials, frontier research and applications. It has key technologies in the R&D, modification and preparation of polymer and regenerative biomaterials and microspheres, enabling translation into market-ready products. With deep R&D and translation expertise and commercial-scale manufacturing capabilities, it is committed to providing high-quality healthcare product solutions over the long term.